Renal sympathetic denervation in patients with treatment-resistant hypertension after witnessed intake of medication before qualifying ambulatory blood pressure

Hypertension

Volumn 62, Issue 3, 2013, Pages 526-532

  Fadl Elmula, Fadl Elmula Mohamed ^a,b   Hoffmann, Pavel ^a   Fossum, Eigil ^a   Brekke, Magne ^a   Gjønnæss, Eyvind ^a   Hjørnholm, Ulla ^a   Kjær, Vibeke N ^a   Rostrup, Morten ^a   Kjeldsen, Sverre E ^a,b   Os, Ingrid ^a,b   Stenehjem, Aud E ^a   Høieggen, Aud ^a  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

drug adherence; renal sympathetic denervation; treatment resistant hypertension

Indexed keywords

ALBUMIN; ANTIHYPERTENSIVE AGENT; CREATININE; DIURETIC AGENT;

ADULT; AGED; AMBULATORY MONITORING; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; CARDIAC PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE URINE LEVEL; DRUG MEGADOSE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY DENERVATION; MALE; MAXIMUM TOLERATED DOSE; MEDICATION COMPLIANCE; PATIENT REFERRAL; PRIORITY JOURNAL; PROTEIN URINE LEVEL; RESISTANT HYPERTENSION; SYSTOLIC BLOOD PRESSURE; TREATMENT RESISTANT HYPERTENSION; WITNESS;

DRUG ADHERENCE; RENAL SYMPATHETIC DENERVATION; TREATMENT-RESISTANT HYPERTENSION;

ADULT; AGED; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; BLOOD PRESSURE MONITORING, AMBULATORY; COMBINED MODALITY THERAPY; DENERVATION; FEMALE; HUMANS; HYPERTENSION; KIDNEY; MALE; MEDICATION ADHERENCE; MIDDLE AGED; RETREATMENT; TREATMENT OUTCOME;

EID: 84883285938     PISSN: 0194911X     EISSN: 15244563     Source Type: Journal    
DOI: 10.1161/HYPERTENSIONAHA.113.01452     Document Type: Article

References (18)

1. De la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, Oliveras A, Ruilope LM. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011; 57: 889-890.
2. Symplicity HTN-2 Investigators. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial. Lancet. 2010; 376: 1903-1909.
3. Gifford RW. An algorithm for the management of resistant hypertension. Hypertension. 1988; 11: I 171-175.
4. Klein LE. Compliance and blood pressure control. Hypertension. 1988;11(3 Pt 2):II61-II64.
5. Ceral J, Habrdova V, Vorisek V, Bima M, Pelouch R, Solar M. Difficult-tocontrol arterial hypertension or uncooperative patients? The assessment of serum antihypertensive drug levels to differentiate non-responsiveness from non-adherence to recommended therapy. Hypertens Res. 2011;34:87-90.
6. Kandzari DE, Bhatt DL, Sobotka PA, O'Neill WW, Esler M, Flack JM, Katzen BT, Leon MB, Massaro JM, Negoita M, Oparil S, Rocha-Singh K, Straley C, Townsend RR, Bakris G. Catheter-based renal denervation for resistant hypertension: Rationale and design of the SYMPLICITY HTN-3 Trial. Clin Cardiol. 2012;35:528-535.
7. Brinkmann J, Heusser K, Schmidt BM, Menne J, Klein G, Bauersachs J, Haller H, Sweep FC, Diedrich A, Jordan J, Tank J. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficultto-control hypertensive patients: Prospective case series. Hypertension. 2012;60:1485-1490.
8. Savard S, Frank M, Bobrie G, Plouin PF, Sapoval M, Azizi M. Eligibility for renal denervation in patients with resistant hypertension: When enthusiasm meets reality in real-life patients. J Am Coll Cardiol. 2012;60:2422-2424.
9. Taler SJ, Textor SC, Augustine JE. Resistant hypertension: Comparing hemodynamic management to specialist care. Hypertension. 2002;39:982-988.
10. Stenehjem AE, Os I. Reproducibility of blood pressure variability, whitecoat effect and dipping pattern in untreated, uncomplicated and newly diagnosed essential hypertension. Blood Press. 2004;13:214-224.
11. Enger E. Selvkontroll av blodtrykk ved behandling av hypertensjon (English abstract). Tidsskr Nor Lægeforen. 1972; 92: 257-263.
12. Boulatov VA, Stenehjem A, Os I. Association between albumin:creatinine ratio and 24-hour ambulatory blood pressure in essential hypertension. Am J Hypertens. 2001;14(4 Pt 1):338-344.
13. Symplicity HTN-1 Investigators. Catheter-based renal sympathetic denervation for resistant hypertension: Durability of blood pressure reduction up to 24 months. Hypertension. 2011; 57: 911-917.
14. Kjeldsen SE, Flaaten B, Eide I, Helgeland A, Leren P. Increased peripheral release of noradrenaline and uptake of adrenaline in essential hypertension? Clin Sci (Lond). 1981;61(Suppl 7):215s-217s.
15. Eide I. Renovascular hypertension in rats immunized with angiotensin II. Circ Res. 1972;30:149-157.
16. Helgeland A. Treatment of mild hypertension: A five year controlled drug trial. The Oslo study. Am J Med. 1980;69:725-732.
17. Persu A, Renkin J, Thijs L, Staessen JA. Renal denervation: Ultima ratio or standard in treatment-resistant hypertension. Hypertension. 2012;60:596-606.
18. Vonend O, Antoch G, Rump LC, Blondin D. Secondary rise in blood pressure after renal denervation. Lancet. 2012;380:778.